Company intelligence / Profile preview
Predix Pharmaceuticals
Lexington, Massachusetts, United Statespredixpharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Predix advanced three internally discovered small-molecule drug candidates into clinical trials targeting CNS disorders and pulmonary hypertension. Its lead program was expected to enter pivotal Phase III trials for generalized anxiety disorder; other programs targeted Alzheimer’s disease and pulmonary arterial hypertension. The company merged with Epix Pharmaceuticals in a $90 million deal but ceased operations by July 2009 due to financial difficulties.
- Therapeutic areas
- PulmonologyPsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Schering AG had an option agreement related to joint agents developed by Epix-Schering after the merger. No major partnerships listed prior to acquisition.
Beyond the preview
Go deeper on Predix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Predix Pharmaceuticals.